Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| FABm006-01 | Mouse | PE-Labeled Monoclonal Anti-Human CD56 Antibody |
|
||
| HGS-S251 | Rabbit | Recombinant Monoclonal Anti-CD56 Antibody, Rabbit (3B6) |
Flow cytometric analysis of Human peripheral blood lymphocytes respectively staining with PE-Labeled Monoclonal Anti-Human CD56 Antibody Mouse IgG2b (Cat. No. FABm006-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Lorvotuzumab mertansine | BB-10901; IMGN-901; huN-901-DM1; IMGN-901-TAP; huN-901-SPP-DM1 | Phase 2 Clinical | Immunogen Inc | Leukemia; Ovarian Neoplasms; Rhabdomyosarcoma; Carcinoma, Merkel Cell; Small Cell Lung Carcinoma; Wilms Tumor; Multiple Myeloma; Sarcoma, Synovial; Neurofibrosarcoma; Neuroblastoma; Pulmonary Blastoma | Details |
| CUBT-906 | CUBT-906 | Phase 2 Clinical | Curative Biotechnology Inc | Glioblastoma | Details |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/CD56 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| IN-B015 | IN-B-015; IN-B00004 | Phase 1 Clinical | HK inno.N Corporation | Neoplasms | Details |
| DXC-006 | DAC-006; DXC-006 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Hematologic Neoplasms; Lung Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
